Real questions from real people exploring psychedelics because, while I’m not a doctor or scientist, “Ask April” is how meaningful dialogue begins.
What You’ll Learn in This Post
Why psilocybin researchers describe integration support as essential to treatment outcomes, not supplementary
What adverse reactions eating disorder patients are experiencing in clinical psilocybin trials and how they are managed
Why cognitive flexibility gained through psilocybin is not automatically translating to behavior change, and what researchers are trying next
How the UCSF trial structure differs from extralegal psilocybin use, and why that difference matters specifically for this population
What the resource cost of psilocybin therapy means for future access, and why shorter-acting compounds like 5-MeO-DMT are entering the conversation
How family systems inadvertently sustain eating disorders and what effective family support looks like in the context of psychedelic treatment
Below are select audience questions from the Psych3d3lic Sal0n “Psilocybin & Disordered Eating” recorded live with Dr. Amanda Downey, clinical psychologist and principal investigator of the UCSF psilocybin trial for anorexia nervosa. Rarely do we have time to do a deep dive into the questions at the Sal0n, so below is more context, more evidence, and more to consider on this emerging field of research. You can listen and watch the full live recording here.
Just before the episode went live, an Imperial College study with a small cohort of 21 participants announced promising outcomes that will inform future trial design. Rising tides, and yet just as Dr. Downey emphasized, funding for clinical trials is how promises and potential become true progress.
The “Disordered Eating” Sal0n featured in the episode took place in April of this year, but it was programmed a year ago—in the summer of 2025. If you live in the Seattle area or are down to livestream the Sal0n’s next season beginning in October, I can attest that you will be privy to history in the making. I’ve been working in this emerging field since 2021, and this year - 2026 - is different. The evidence? The first FDA-approved psychedelic pharmaceutical is less than a year from approval. In 2025, 11 million Americans consumed psilocybin. I’m no longer explaining what the word “integration” means—it’s now in the zeitgeist.
Hell, the audience questions at this April 2026 Sal0n provide evidence.
The audience who came to this Salon knew things. They were clinicians, family members, people who work in higher levels of care, people who had already sent patients to Oregon on their own recognizance and were watching to see what happened. The questions they asked were not beginner questions. They were the hard ones: what about integration without clinical support, what about adverse reactions, why hasn’t anything worked in forty years, and what does the cognitive flexibility psilocybin produces actually translate to in terms of behavior change? Dr. Downey did not flinch from any of them.
In future emails, I’m thrilled to provide updates about Sal0n guests from last season—book published, documentary released, and so much more!
Enjoy today’s deep dive.
Take care,
April
This question came from a clinician who works in higher-level eating disorder care and has witnessed panic reactions in people who find the loss of bodily control during a psilocybin experience intolerable. It is a well-founded concern.
Dr. Downey confirmed that this tracks with what the UCSF trial is seeing. Patients with anorexia are often profoundly disconnected from physical sensation. That disconnection is frequently protective. it has allowed them to survive. Psilocybin can produce a sudden, intense embodied experience, and tolerating five hours of that, feeling things in a body they have spent years attempting to control or erase, is not just difficult. It can be destructive if it happens without adequate preparation and support.
The clinical finding that holds across multiple psychedelic trials is this: difficult experiences that are well-supported can be among the most therapeutically powerful. The same experiences without support can cause significant harm. That distinction is not theoretical. It is what the research consistently shows, and it is why underground or extralegal use in this population specifically concerns Dr. Downey more than unsupported use in most other contexts.
This came from a clinician who had worked at UCSD, where an earlier psilocybin trial for anorexia showed similar results. A patient returned from an independent session in Oregon with expanded thinking, a different relationship to her body and food, and then did not change her behavior. It was a question about the gap between insight and action.
Dr. Downey described the results at UCSF as a mixed bag. Some participants have shown meaningful behavior change. Others have experienced significant shifts in how they think and feel without corresponding changes in eating behaviors or weight. She does not have a full answer, and she said so plainly.
What the trial is attempting, to address the gap: bringing the family system into the treatment model. Family systems reorganize around a mental illness over time, often without anyone noticing, in ways that can inadvertently sustain the disorder. Part of the UCSF approach is helping families recognize those patterns and restructure around the possibility of change. Not coercive change, not food checklists. Self-directed, patient-led change, with the family learning to support a different trajectory.
The trial also conducted large focus group studies with providers across California who are not involved in psychedelic therapy, therapists, nurses, doctors, dieticians, to understand what they would need to know in order to support patients returning from psilocybin sessions into their ongoing care. The goal is building a wider network of support that can help translate cognitive openness into sustained behavioral shift.
Dr. Downey also named the harder frame: if a patient’s weight does not change but their quality of life improves and their thinking becomes more flexible, that may constitute a meaningful outcome. Not the outcome researchers want for everyone. But from a harm reduction standpoint, movement in any direction that matters to the patient has value.
There has been some resistance, Dr. Downey said, and it comes from genuine care for patients. The deepest concern from providers involves younger patients: how do you obtain meaningful informed consent from an adolescent for an experience that is genuinely difficult to describe, let alone predict? Consent from adults already requires significant preparation to be ethically sound. Consent from a young person, who may not have the developmental or linguistic tools to understand what they are agreeing to, is a harder question that the field has not fully answered.
The question of preparation came up here as well. In a clinical trial, preparation is mandated. Participants complete it. Extralegal (the “underground”) use does not come with that structure, and the minimum viable preparation for a psilocybin experience, particularly for someone with an eating disorder, is not a floor Dr. Downey is comfortable naming. She wants to think about maximum preparation, not minimum.
Participants must meet specific medical benchmarks to be cleared for dosing, which are outlined in the trial’s inclusion and exclusion criteria. The preparation phase involves three sessions before each high-dose administration, each up to two hours long, with time both for the participant individually and with caregivers present.
What is not captured in the official protocol is the volume of contact between the research team and participants outside formal sessions. Dr. Downey described it as constant: surveys, phone calls, check-ins, and noted that this nonspecific contact is itself therapeutically meaningful. The study runs between eight and twenty weeks, which means participants can spend months in relationship with the research team before a dosing day. That relationship is part of the container, not separate from it.
Participants come from across the country, many arriving without any prior relationship to the UCSF team. The trial conducts thorough medical records reviews to develop a comprehensive picture of each person before they begin.
Q: How do I find a psychedelic guide?
·
Jun 12
How do I find a licensed psilocybin facilitator? Start with the state licensee directories above, then cross-reference vetted third-party directories. Narrow your list by location (proximity to the airport), setting (access to the outdoors), credentials, and specialization (sexual trauma, PTSD, mindfulness).
Family systems, as Dr. Downey described them, reorganize around mental illness the way any system reorganizes around a disruption: by moving toward homeostasis. While that reorganization is usually well-intentioned, it is often invisible to the people inside it - as are its consequences. Patterns of accommodation that formed to reduce distress during acute illness can become the infrastructure that sustains the illness over time.
Effective family support, in and out of psychedelic contexts, involves recognizing those patterns, understanding how the family has adapted, and building the capacity to respond differently in ways that support the person’s own movement toward change rather than protecting the system’s equilibrium. That work requires support for family members, who are effecrively inside the illness as well.
Yes, it is in the conversation. The driver is access, not experience quality. Psilocybin therapy as currently designed is extraordinarily resource-intensive: two PhD-level psychologists present for every eight-hour dosing session, multiple preparation and integration sessions, medical oversight throughout. The cost structure makes it inaccessible to most of the people who need it. A shorter-acting psychedelic could reduce that resource burden and expand who can realistically receive treatment.
5-MeO-DMT operates through a different mechanism than psilocybin and produces a qualitatively different experience, one that many practitioners describe as more intense and less amenable to narrative processing. Whether that mechanism serves eating disorder treatment in a comparable way is unknown. The medical considerations are also distinct. But Dr. Downey’s framing of where the field is right now: everything is on the table, and shorter-acting options are reasonable to explore.
ARFID (Avoidant Restrictive Food Intake Disorder) is a relatively new DSM-5 diagnosis covering a heterogeneous patient population. The presentations vary significantly: sensory or textural aversion to foods, unexplained loss of appetite unrelated to depression or another condition, intense fear of choking or vomiting. Because the presentation varies so much, it is harder to design a clean trial.
There is significant enthusiasm in the research community for an ARFID study. There is not yet real traction. Dr. Downey’s characterization of the funding landscape was candid: eating disorders are underfunded relative to other mental health conditions, and ARFID is newer to the scene than anorexia.
OCPD (Obsessive Compulsive Personality Disorder) was addressed at the Salon because there is high co-occurrence between OCPD and anorexia, and both conditions involve significant cognitive rigidity. Researchers are curious and cautious about how people with more severe rigidity experience psilocybin, whether the characteristic grip loosens or tightens under the influence of a substance that does not respond to control.
The throughline of this conversation is the gap between what psilocybin appears to open, cognitively, emotionally, relationally, and what the support structures required to translate that opening into lasting change actually cost. The medicine may be doing something genuinely new for a population that has had almost nothing to reach for. Whether that potential gets realized depends entirely on what surrounds the session, who is there, for how long, and how the system around the patient reorganizes to hold the change.
The Psychedelic Salon on Disordered Eating covered all these questions and so much more. You can watch or listen to the full live recording on Substack, YouTube, or wherever you listen to podcasts.
Take care,
April
Comments
Nothing yet. Say the first thing.
Sign in to join the conversation.